GEN2d
Insilico Plans Pivotal Trial for AI-Based IPF Candidate
The topline data showed ISM001-055 to have improved the forced vital capacity (FVC) of IPF patients studied 12 weeks after ...
pharmaphorum2d
Making the case for pharmaceutical IP management
Ranbaxy reportedly reaped $500 million in sales from its knockoff of Pfizer's cholesterol pill Lipitor during its first six months on the market. The competitive nature of the market makes patents ...
pharmaphorum4d
Rethinking investment and market access in Canada
In turn, insurers are forcing generic substitution of blockbusters such as Lipitor, Crestor and Plavix ... Pfizer, Roche, Sanofi Aventis and Sanofi Pasteur. He has been closely involved in the ...
Medscape5d
Managing Recalcitrant Hypercholesterolemia in Patients on Current Best Standard of Care
GF Watts has received lecture fees and has served as an advisor to Sanofi-Aventis, Genzyme and Amgen Corporation. The authors have no other relevant affiliations or financial involvement with any ...
Medscape1d
Effectiveness and Tolerability of Every-Other-Day Rosuvastatin Dosing in Patients with Prior Statin Intolerance
Background: Statins are generally well tolerated, but some patients discontinue therapy secondary to adverse effects. Dosing a statin (rosuvastatin) every other day (EOD) may provide significant ...
Indiatimes3d
Sanofi India Share Price
Sanofi India Ltd., incorporated in the year 1956, is a Mid Cap company (having a market cap of Rs 14,385.85 Crore) operating in Pharmaceuticals sector. Sanofi India Ltd. key Products/Revenue Segments ...